Molecular genetics and targeted therapeutics in biliary tract carcinoma

World Journal of Gastroenterology : WJG
Eric I Marks, Nelson S Yee

Abstract

The primary malignancies of the biliary tract, cholangiocarcinoma and gallbladder cancer, often present at an advanced stage and are marginally sensitive to radiation and chemotherapy. Accumulating evidence indicates that molecularly targeted agents may provide new hope for improving treatment response in biliary tract carcinoma (BTC). In this article, we provide a critical review of the pathogenesis and genetic abnormalities of biliary tract neoplasms, in addition to discussing the current and emerging targeted therapeutics in BTC. Genetic studies of biliary tumors have identified the growth factors and receptors as well as their downstream signaling pathways that control the growth and survival of biliary epithelia. Target-specific monoclonal antibodies and small molecules inhibitors directed against the signaling pathways that drive BTC growth and invasion have been developed. Numerous clinical trials designed to test these agents as either monotherapy or in combination with conventional chemotherapy have been completed or are currently underway. Research focusing on understanding the molecular basis of biliary tumorigenesis will continue to identify for targeted therapy the key mutations that drive growth and invasion of bi...Continue Reading

References

Sep 1, 1994·Journal of Gastroenterology and Hepatology·K OkadaA Watanabe
May 1, 1994·Seminars in Liver Disease·J N Vauthey, L H Blumgart
Apr 1, 1997·Proceedings of the National Academy of Sciences of the United States of America·M TsujiiR N DuBois
Nov 13, 1998·Science·M H CardoneJ C Reed
Oct 20, 1999·Journal of Hepato-biliary-pancreatic Surgery·I I Wistuba, J Albores-Saavedra
May 10, 2000·The Oncologist·G McMahon
Jun 12, 2002·The American Journal of Pathology·Ignacio I WistubaAdi F Gazdar
Jun 24, 2003·The American Journal of Pathology·Donna E HanselAnirban Maitra
Apr 2, 2004·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Zichen ZhangAlphonse E Sirica
Jun 8, 2004·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·David GoldenbergAnirban Maitra
Jun 29, 2004·Virchows Archiv : an International Journal of Pathology·Angelica A SaettaEfstratios Patsouris
Jun 1, 2005·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·M A SilvaD F Mirza
Aug 10, 2005·Virchows Archiv : an International Journal of Pathology·Toru FurukawaSuguru Yonezawa
Nov 8, 2005·Nature·David B SolitNeal Rosen
Mar 23, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Francesco LeoneMassimo Aglietta
Jul 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip A PhilipCharles Erlichman
Nov 28, 2006·Biochimica Et Biophysica Acta·James A McCubreyRichard A Franklin
Mar 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tammie C YehEli Wallace
Apr 14, 2007·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Yoh ZenYasuni Nakanuma
Aug 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Beata HerbergerMartin Filipits
Sep 21, 2007·Nature Reviews. Cancer·Javier A Menendez, Ruth Lupu
Jan 9, 2008·Genes, Chromosomes & Cancer·Marc-Oliver RienerWolfram Jochum
May 2, 2008·The Oncologist·Aram F Hezel, Andrew X Zhu
Aug 30, 2008·British Journal of Cancer·M-O RienerW Jochum
Sep 5, 2008·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Betsy PaulJennifer Thompson
Sep 17, 2008·Oncogene·T L Yuan, L C Cantley
Jan 27, 2009·Cancer Chemotherapy and Pharmacology·Ramesh K RamanathanDavid R Gandara

❮ Previous
Next ❯

Citations

Jul 22, 2017·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Chun-Nan YehChung-Shan Yu
Mar 31, 2018·Cancer Immunology, Immunotherapy : CII·Daniel Rojas-SepúlvedaFlavio Salazar-Onfray
Jun 24, 2017·HPB Surgery : a World Journal of Hepatic, Pancreatic and Biliary Surgery·Christine S M LauRonald S Chamberlain
May 27, 2020·The Journal of Experimental Medicine·Qingxin ZhouZhiyong Zhang
Apr 12, 2017·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Xin ZhuangHua-Xin Duan
Sep 28, 2016·World Journal of Gastroenterology : WJG·Nicola Fusco, Silvano Bosari
Jan 6, 2019·Biomedicines·Nelson S Yee, Nikki P Lee
Nov 19, 2018·Pathology Oncology Research : POR·Gábor LendvaiKatalin Borka
Aug 21, 2020·European Journal of Pediatric Surgery : Official Journal of Austrian Association of Pediatric Surgery ... [et Al] = Zeitschrift Für Kinderchirurgie·Marie UeckerJoachim F Kuebler
Sep 4, 2020·Medicines·Angela Dalia RicciGiovanni Brandi
Jun 16, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ian Chau
Nov 17, 2020·Frontiers in Oncology·Lara P FernándezAna Ramírez de Molina
Feb 17, 2021·Cancer Treatment and Research Communications·Alessandro Rizzo, Giovanni Brandi
Apr 3, 2021·Cancer Treatment and Research Communications·Alessandro RizzoGiovanni Brandi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.